Skip to main content

Table 2 Parameters for final model (Model 2 [E 5 ≠ E 10 ]) with all covariates

From: Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

Variable Units Mean value, θ ± SE Intersubject variability, η ± SE
Placebo growth rate, r 10-3 cm/day 46.0 ± 5.7 3.5 ± 2.1
Drug effect of 10 mg, E 10 10-3/day 3.9 ± 0.5 0.3 ± 0.2
Drug effect of 5 mg, E 5 10-3/day 2.3 ± 0.5 0.2 ± 0.2
Multiplicative effect of baseline SLD on placebo growth rate, θ1   0.4 ± 0.2 NA
Multiplicative effect of baseline SLD on drug effect, θ2   −0.7 ± 0.2 NA
Residual error, σε cm 1.1 NA
  1. NA, not applicable; SE, standard error; SLD, sum of the longest tumor diameters.
  2. Intersubject variability (η) denotes the standard deviation of the parameter distributions.